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The development of novel, targeted delivery agents
for anti-cancer therapies requires the design and
optimization of potent and selective tumor-targeting
agents that are stable and amenable to conjugation
with chemotherapeutic drugs. While short peptides
represent potentially an excellent platform for these
purposes, they often get degraded and are elimi-
nated too rapidly in vivo. In this study, we used a
combination of nuclear magnetic resonance-guided
structure-activity relationships along with biochem-
ical and cellular studies to derive a novel tumor-
homing agent, named 123B9, targeting the EphA2
tyrosine kinase receptor ligand-binding domain.
Conjugating 123B9 to the chemotherapeutic drug
paclitaxel (PTX) via a stable linker results in an agent
that is significantly more effective than the unconju-
gated drug in both a pancreatic cancer xenograft
model and amelanoma lung colonization andmetas-
tases model. Hence, 123B9 could represent a prom-
ising strategy for the development of novel targeted
therapies for cancer.
INTRODUCTION
The Eph receptors (14 subtypes are found in humans) represent
the largest family of receptor tyrosine kinases (RTKs), consisting
of eight EphA and six EphB subtypes based on sequence homol-
ogy andbindingpreference for their ephrin ligands (Gale andYan-
copoulos, 1997; Kullander and Klein, 2002; Murai and Pasquale,
2003). The Eph family contains a conserved domain organization
with an extracellular portion consisting of a ligand-binding
domain (LBD) followed by a cysteine-rich domain, an epidermal
growth factor (EGF)-like domain and two fibronectin type III do-
mains. The intracellular portion contains a juxtamembrane region
with several conserved tyrosine residues followed by a tyrosine
kinase domain, a sterile a motif protein-protein interaction
domain and a C-terminal PDZ-binding motif (Pasquale, 2008).876 Chemistry & Biology 22, 876–887, July 23, 2015 ª2015 Elsevier LEphA2 is overexpressed in several types of cancer. As a
consequence, it fails to efficiently interact with its ligands on
adjacent cells, leading to the accumulation of unphosphorylated
EphA2 (Landen et al., 2005; Wykosky and Debinski, 2008). Over-
expression of EphA2 is implicated in several critical aspects of
oncogenesis such as cytoskeletal organization, cell adhesion,
migration, metastasis, proliferation, and angiogenesis (Brannan
et al., 2009; Brantley-Sieders, 2012; Faoro et al., 2010; Fournier
et al., 2006; Kinch et al., 2003; Zhuang et al., 2010), making
EphA2 a promising target for cancer therapeutics.
Agonistic peptides were identified via phage display tech-
niques mimicking the ephrin ligands. These peptides induce re-
ceptor endocytosis and activate EphA2 phosphorylation leading
to downstream signaling (Koolpe et al., 2002; Mitra et al., 2010;
Pasquale, 2005). Other EphA2-targeting approaches have been
reported, including small molecule EphA2 targeting agents
(Chang et al., 2008; Noberini et al., 2008), viral vectors express-
ing soluble ephrin-A1 protein (Brantley-Sieders et al., 2008), and
RNAi blocking EphA2 expression (Carles-Kinch et al., 2002; Dux-
bury et al., 2004; Kikawa et al., 2002).
One of the key challenges in current chemotherapy for cancer
treatment is how to selectively deliver therapeutic agents to can-
cer cells to maximize their efficacy while limiting off-target
effects against normal tissues. Because of its expression pat-
terns in tumor cells, the EphA2 receptor has been considered
as a promising target for tumor-homing, targeted delivery strate-
gies. For example, a Pseudomonas bacterial toxin (PE38QQR)
has been conjugated to ephrin-A1; the resulting chimeric protein
was toxic to glioblastoma, breast, and prostate cancer cells that
express high levels of EphA2 (Wykosky et al., 2007). More
recently, a phase 1 studywas conducted on a small cohort of pa-
tients with solid tumors (Annunziata et al., 2013) to evaluate the
safety of MEDI-547, an antibody-drug conjugate (ADC) consist-
ing of a human anti-EphA2 monoclonal antibody (1C1) linked
to maleimidocaproylmonomethyl auristatin phenylalanine. The
study had to be discontinued because of severe side effects of
the initial dose, which were likely caused by MEDI-547 cross-re-
acting with other proteins or by premature delivery of the drug
(Annunziata et al., 2013).
Nonetheless, EphA2 remains a promising target for the design
of innovative targeted delivery strategies using perhapsmore se-
lective ADCs (Annunziata et al., 2013) or agonistic peptides,td All rights reserved
which, based on our recent studies, may be particularly suitable
for this application (Barile et al., 2014; Wang et al., 2012, 2013).
Agonistic peptides that bind to EphA2 are promising substitutes
for antibodies as selective tumor-homing agents because they
are easier to synthesize, less prone to cause immunogenic
issues, and generally present more favorable tissue penetration
properties than macromolecules.
Recently, two 12-mer peptides, YSA (amino acid sequence:
YSAYPDSVPMMS) and SWL (amino acid sequence:
SWLAYPGAVSYR), have been identified via phage display tech-
niques as EphA2 agonists. Although both target the LBD of
EphA2, the YSA peptide binds with higher affinity than the
SWL peptide (IC50 [inhibitory concentration 50%] values in the
low micromolar range) in both ELISA displacement assays
(Koolpe et al., 2002) and in direct binding studies (Barile et al.,
2014; Wang et al., 2012, 2013). YSA binding induces EphA2
forward signaling, resulting in EphA2 phosphorylation and inter-
nalization (Koolpe et al., 2002). Hence, the YSA peptide is
considered as a potential tumor-homing agent, which can deliver
therapeutic agents to specific tumor sites and facilitate their
entry into the cytoplasm of cancer cells. Indeed, YSA-functional-
ized nanogels have been used to deliver siRNAs that downregu-
late the EGF receptor in EphA2-expressing ovarian cancer cells,
altering their response to chemotherapy (Blackburn et al., 2009;
Dickerson et al., 2010).
Recently, we demonstrated using cellular imaging and in vivo
xenograft studies that conjugation of the YSA peptide or
an improved version called YNH (amino acid sequence:
YSAYPDSVP-Nle-Hsr-S, where Nle and Hsr represent the non-
natural amino acids l-norleucine and l-homoserine, respectively)
with quantum dots and paclitaxel (PTX) selectively delivers the
agents to EphA2-expressing PC3 prostate cancer cells (Wang
et al., 2012, 2013).
However, the YSA and YNH peptides have a relatively short
half-life (t1/2) in plasma, severely limiting their application in
cellular and in vivo studies (Barile et al., 2014). We report here
on novel YNH derivatives that retain their binding properties
and selectivity for the EphA2-LBDwhile also possessing a signif-
icant t1/2 in plasma and in vivo. In particular, our data suggest
that the agent 123B9 could replace the YSA and SWL peptides
in studying the role of EphA2 in tumorigenesis in cells in culture
and in vivo and for the design of novel targeted drug delivery
strategies. We report on the design, synthesis, and characteriza-
tion of this novel series using biophysical and cellular assays
along with in vivo models of pancreatic cancer and melanoma.
RESULTS
Optimization Strategy to Derive a Novel EphA2-LBD
Binding Agent
In our previous studies, we developed a YSA-based targeting
agent containing the chemotherapeutic drug PTX (Wang et al.,
2012, 2013). Our studies demonstrated that the YSA-PTX conju-
gate was more effective than PTX alone at inhibiting tumor
growth in a prostate cancer xenograft model, as significantly
higher levels of the drug were delivered to the site of the tumor
(Barile et al., 2014; Wang et al., 2012, 2013). In a first attempt
to improve the stability of these agents in vivo, the YSA peptide
was replaced by the peptides YNH (YSAYPDSVP-Nle-Hsr-S)Chemistry & Biology 22,and dYNH (ySAYPDSVP-Nle-Hsr-S). In both peptides, the two
easily oxidized methionine residues of YSA were replaced
by two unnatural residues, l-norleucine and l-homoserine. In
dYNH the first residue of was also changed to d-tyrosine (Barile
et al., 2014; Wang et al., 2013). Of the three peptides, dYNH ex-
hibited the longest t1/2 in plasma (>1 hr), while YSA and YNH ex-
hibited a very short t1/2 (15–20 min) (Barile et al., 2014; Wang
et al., 2012, 2013). However, compared with YNH, incorporation
of the d-Tyr at the N terminus decreased the EphA2 binding
affinity about 10-fold. Recent more detailed studies from our
laboratory confirmed that the instability of YSA or YNH in plasma
is caused primarily by aminopeptidases cleaving the N-terminal
Tyr residue, consistent with the longer plasma t1/2 of dYNH
(Barile et al., 2014).
Hence, while replacing the first amino acid with a d-Tyr re-
sulted in a peptide with improved t1/2 in plasma, its EphA2 bind-
ing affinity was compromised (Barile et al., 2014; Wang et al.,
2012, 2013). Therefore, we sought to devise alternative strate-
gies that would allow improving plasma stability of YNH without
compromising its binding affinity for the EphA2-LBD. First, we
replaced natural amino acids in positions P-3, P-4, P-5, and
P-6 (counting from the N-terminal P-1, Tyr residue) with a variety
of unnatural analogs. However, all these attempts had little or
no effect on improving either EphA2 binding affinity or plasma
stability (not shown). As mentioned above, we recently deter-
mined using quantitative nuclear magnetic resonance (NMR)
spectroscopy and mass spectrometry (MS) analyses that the
rate limiting degradation events of YNH and YSA occur at the
N-terminal residue (Barile et al., 2014). Hence, our focus shifted
on replacing the P-1 tyrosine with benzyl acids lacking the N-ter-
minal amino group necessary for recognition by aminopepti-
dases (Heavner et al., 1986; Lugrin et al., 1991). To expedite
the synthesis, purification, and evaluation of various P-1
benzyl-acid YNH derivatives, the 8-mer peptide SAYPDSVP
was synthesized via solid-phase methods and used as reagent
for the coupling with various acids. While deleting the last three
residues in YSA, YNH, or dYNH attenuated the binding of the re-
sulting 9-mer peptides, their respective rank ordering of binding
remained the same, suggesting that the binding properties of
these 9-mers are largely similar to the 12-mers and still sensitive
to the nature of the first residue. Hence, we decided to omit the
last three residues in our SAR studies, as this simplifies the syn-
thesis of analogs aimed at identifying an optimal residue at posi-
tion P-1. Subsequently, we included back the last three amino
acids into the optimal 9-mer as a last step.
To rapidly and unambiguously rank the affinity of the synthe-
sized 9-mers, we used a simple NMR-based binding assay using
recombinant EphA2-LBD (residues 27–200) (Barile and Pellec-
chia, 2014). In particular we used the 1H-aliph 1D NMR method
to detect binding: 1D 1H NMR spectra of the EphA2-LBD are
collected in the absence and presence of test compounds at a
given protein to ligand ratio and binding is detected by
comparing these spectra in the aliphatic region (d < 0.8 ppm)
(Barile and Pellecchia, 2014). In our experience, protein NMR
spectroscopy is themost sensitive and reliable method to detect
and rank ligand binding, especially when ligands possess affin-
ities in the micromolar range, such as the 9-mers under investi-
gation (Barile and Pellecchia, 2014; Pellecchia et al., 2008).
Hence, a rapid and unambiguous rank ordering of a series of876–887, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 877
Figure 1. Evaluation and Comparison of the
Peptide Binding Properties for the EphA2-
LBD by NMR
(A) 1D 1H NMR spectra (aliphatic region d < 0 ppm)
of 10 mM EphA2-LBD acquired in the absence
(black, DMSO) and presence of 100 mM dYSA-
9mer (red), YSA-9mer (blue), and 123B4 (purple).
The diagnostic peaks peak-1, -2, and -3 ex-
periencing shifts upon binding are labeled as
peak-10, -20, and -30 respectively.
(B) Superposition of 2D [15N, 1H]-HSQC spectra of
50 mM 15N-labeled EphA2-LBD recorded in the
absence (red) and presence (green) of 100 mM
123B9.
(C) Superposition of 2D [15N, 1H]-HSQC spectra of
50 mM 15N-labeled EphA2-LBD acquired in the
absence (red) and presence (blue) of 100 mM YNH.
(D) Superposition of 2D [15N, 1H]-HSQC spectra of
100 mM 15N-labeled EphA2 acquired in the pres-
ence of 200 mMof YNH (blue) or 123B9 (green). The
similar chemical shift perturbations induced by
these two agents suggests that they adopt a fairly
similar binding mode.congeneric compounds or peptides can be achieved by
comparing perturbations induced by each test ligand on diag-
nostic protein peaks in the 1D 1H NMR protein aliphatic region
spectrum, measured at a given ligand and protein concentration
(Barile and Pellecchia, 2014). This approach is particularly useful
when the chemical structures of test ligands are highly similar.
Hence, as a reference we first collected 1D 1H NMR spectra of
EphA2-LBD in the absence and presence of 100 mM YSA-9mer
and dYSA-9mer. Although the resonance assignments for
EphA2-LBD are not available yet, useful binding information
was determined by annotating the spectral perturbations upon
binding of the known ligands at various concentrations. As
shown in Figure 1, YSA-9mer at the concentrations tested
caused the complete loss of peak-1 and the appearance of a
new peak (peak 10), whereas dYSA-9mer only caused a
decrease of peak-1 with no new peaks observed. We infer that
these differences are a reflection of the relative binding affinities
of YSA-9mer and dYSA-9-mer. Similarly, additional changes in
the 1D 1H NMR spectra of EphA2-LBD in the presence of these
ligands were observed. For example, peak-2 (Figure 1) de-
creases in intensity upon binding of dYSA-9mer, while a new
peak (peak-20) appears in the presence of YSA-9mer (Figure 1).
Finally, the binding of the peptides perturbs peak-3, leading to
a shifted peak-30 (Figure 1). Notably, upon peptide titrations,
the changes of peak-1, -2, and -3 did not occur simultaneously
but appeared sequentially: first, the intensity of peak-1
decreased with the appearance of peak 10 followed by a
decrease in the intensity of peak-2, followed by peak-2
and peak-3 shifts to peaks-20 and -30. Based on these ob-
servations, we established rough rank ordering criteria for the
binding of YSA-9mer-related peptides, using an arbitrary scale878 Chemistry & Biology 22, 876–887, July 23, 2015 ª2015 Elsevier Ltd All rights reservedof rank = 1 (similar to dYSA-9mer) to
rank = 5 (similar to YSA-9mer) as
described in the legend to Table 1.
Several structure-activity relationship
correlations emerged. First, as expected,elimination of the amino group in the YSA-9mer (or dYSA-9mer)
resulted in compound 120F5 that was even less active in binding
EphA2-LBD than YSA-9mer (Table 1). Furthermore, correlative
analysis of the binding potency of other synthesized compounds
could be studied in terms of the electronic (Hammet, s) and hy-
drophobic (Hansch, p) parameters (Hansch et al., 1991; Leo and
Hansch, 1999) of the substituents in P-1. Interestingly, isosteric
substitutions of the hydroxyl group (sp = 0.37; p = 0.67) on
120F5 did not significantly improve the affinity (i.e., compound
120H5, with p–NH2, rank = 1, and sp = 0.66; p = 1.23). On
the contrary, para substituents with nearly opposite electrostatic
but similar hydrophobic properties to the hydroxyl seem to
favor the interactions with the receptor (i.e., compounds 120A5
(rank = 3, p–CN, sp = 0.66; p = 0.57) R 120H8 (rank = 3,
p–SO2NH2, sp = 0.70; p = 1.82) > 120F11 (rank = 2, p–F,
sp = 0.06; p = 0.14) > 120F5 (rank = 1, p–OH, sp = 0.37;
p =0.67)). Similar observations suggest thatmore hydrophobic
substituents are preferred in the meta position (i.e., 120G8
(rank = 4, m–Cl, p = 0.71) > 123A12 (rank = 3, m–CH3,
p = 0.56) > 120G7 (rank = 2, m–F, p = 0.14)). Hence, the ideal
compound may present a substituent with a larger sp and a
negative p in the para position along with a hydrophobic substit-
uent in themeta position. This could be accomplished by prepar-
ing a p–SO2NH2, m–Cl compound or by introducing an electron
withdrawing oxygen atom in the side chain. The latter option was
easier to synthetize based on available reagents. Hence, these
considerations led to compound 123B4 (rank = 5, p–F, m–Cl)
(Table 1). In the NMR binding assay, 123B4 caused a complete
loss of peak-1 and the largest shift of peak-2 with the appear-
ance of peak-10, similar to what was observed with the YSA-
9mer, suggesting that 123B4 possessed the highest binding
Table 1. Chemical Structures and EphA2-LBD Binding Rank Ordering of Synthesized YSA Derivatives
Compound ID R Rank Ordering by NMRa Compound ID R Rank Ordering by NMRa
123B4 5 120G5 2
YSA (or
YNH)-9mer
5 120G6 2
120G8 4 120G7 2
123A10 4 120H3 2
123A12 4 120H6 2
120H8 3 120H7 2
123A11 3 123A2 2
120A5 3 120F11 2
123A7 3 120F9 2
123B5 2 dYSA-9mer 1
120H5 1 120F5 1
aRank ordering according to the following criteria: 1, peak 1 and peak 2 intensity decrease; 2, same conditions as in 1 but with peak 2moving to peak 20;
3, same conditions as in 2 but with peak 30 appearing at a chemical shift up to 0.35 ppm; 4, same as in 2 but with peak 30 shifting at a chemical shift
between 0.35 and 0.4 ppm; 5, same as in 2 but with peak 30 shifting at a chemical shift <0.5 ppm.
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Table 2. Comparison of Binding Affinities for the EphA2-LBD of
YSA and YNH Peptides with Their Corresponding P-1 Optimized
Analogs
Compound ID Chemical Structure
Kd by
ITC (mM)
123B9 4.0
YNH-12mer 9.0
123B7 9.0
YSA-12mer 5.3affinity for EphA2-LBD among the synthesized and tested ana-
logs (Table 1). Therefore, we decided to ascertain whether this
series of peptide mimetics retains the same selectivity and activ-
ity both in cell culture and in vivo of the corresponding YNH or
YSA peptides. Hence, EphA2-binding peptide mimetics were
synthesized, including the last three residues of YSA and YNH
(i.e., introducing methionine-methionine-serine and norleucine-
homoserine-serine, respectively) at the C terminus of 123B4 to
generate 123B7 and 123B9, respectively (Table 2). These repre-
sent a first generation of P-1 optimized versions of YSA and
YNH/dYNH, respectively.
Evaluating the Binding Properties of the Novel Agents
To further evaluate the binding properties of our selected agents,
we performed qualitative NMR binding studies and quantitative
isothermal titration calorimetry (ITC) measurements using re-
combinant EphA2-LBD to compare the P-1 optimized peptides
(123B9, 123B7, and 123B4) with their corresponding reference
peptides (YNH, YSA, and YSA-9mer, respectively). First, 2D
[1H,15N] heteronuclear single quantum correlation (HSQC)
spectra of 15N-labeled EphA2 LBD (residues 27–200) were
collected. As expected from the 1D 1H NMR aliphatic spectral
changes, large chemical shift perturbations were observed in
the 2D [1H,15N] HSQCs, indicating specific peptide interactions
(Figures 1B and 1C). Most importantly, the similar pattern of
chemical shift perturbations upon complexation with 123B9 or
YNH suggested that the two peptides bind to EphA2 with a
similar pose (Figure 1D). ITC analysis further confirmed that
123B9 binds to the isolated recombinant LBD of EphA2 with a
Kd value of 4.0 mM (Table 2), whereas the YNH peptide showed
a Kd value of 9.0 mM (Table 2). Similarly, the Kd value of 123B7
was 9.0 mM and its corresponding peptide, YSA, was 5.3 mM
(Table 2).880 Chemistry & Biology 22, 876–887, July 23, 2015 ª2015 Elsevier LHence, 123B9 represents a P-1 optimized peptide with
EphA2-binding affinity similar to YSA and YNH, but lacking the
N-terminal amide.
Plasma Stability Studies
To determine the relative resistance to proteolytic degradation of
our agents in vivo, plasma stability assays were first performed
in vitro using liquid chromatography (LC)-MS. EphA2 ligand
123B9, lacking the free N-terminal amine, was very stable, with
over 95% intact compound detected in plasma after 120 min
(Figure 2A; t1/2 >> 2 hr). Compared with 123B9, YNH displayed
amarkedly shorter t1/2 (–20 min) and it was completely degraded
after 60 min (Figure 2B). These data clearly indicate that the sta-
bility of the peptide was significantly improved after the P-1 opti-
mization. Similar comparisons with other pairs of P-1 optimized
peptides and their corresponding non-optimized peptides,
namely 123B7 versus YSA (Figures 2C and 2D) and 123B4
versus YSA-9mer (Figures 2E and 2F), also suggested that delet-
ing the free, N-terminal amine significantly improved peptide
stability.
To further investigate the stability of 123B9 in vivo, we carried
out preliminary pharmacokinetic (PK) studies after intravenous
(IV) administration in mice. The mean plasma concentration
over time following 123B9 IV administration (30 mg/kg, n = 2)
indicated that the compound was detectable in vivo at each
time point tested (30 min, 1 hr, 2 hr, 4 hr), with a mean concen-
tration in plasma of 447 ± 268 ng/ml and 569 ± 86 ng/ml still
detectable at 2 hr and 4 hr, respectively. In comparison, the
in vivo t1/2 of YNH was very short (less than a few minutes),
with no compound detectable 30 min after IV administration
(30 mg/kg, n = 2), in agreement with the plasma stability mea-
surements. While these studies did not provide a full PK profile
for the peptide, the comparison with YNH clearly paralleled the
increased stability in plasma of 123B9.
123B9 Selectivity and Cellular Activity
To ascertain whether 123B9 could be used to selectively target
EphA2, similar to our previously reported PTX conjugate YNH-
L2-PTX, we next synthesized 123B9-L2-PTX and a scrambled
control XDP-L2-PTX (Figure 3A; Supplemental Information).
When tested under similar experimental conditions, ITC mea-
surements clearly indicated that 123B9-L2-PTX did not appre-
ciably inhibit the LBDs of the most closely related EphA3 and
EphA4 receptors. These findings are similar to what we previ-
ously observed with YSA and YNH (Figure 3B) (Barile et al.,
2014; Wang et al., 2012, 2013) and clearly suggest that our
new agent was highly selective for its intended target.
Previously, we used fluorescence microscopy in cellular as-
says to assess the ability of the EphA2 targeting peptide drug
conjugates labeled quantum dots to be internalized in EphA2 ex-
pressing breast and prostate cancer cells (Barile et al., 2014;
Wang et al., 2012, 2013). As mentioned above, both 123B9
and YNH induced fairly similar chemical shift perturbations to a
15N-labeled EphA2-LBD (Figure 1D), suggesting that the two
agents interact with the receptor in a similar mode. Like YNH,
123B9 may therefore also work as an agonist. Accordingly,
123B9-L2-PTX and YNH-L2-PTX but not XDP-L2-PTX caused
EphA2 tyrosine phosphorylation in PC3M prostate cancer cells,
indicative of receptor activation (Figure 3C). These resultstd All rights reserved
Figure 2. Comparative Peptide Stability in
Plasma and In Vivo with Selected EphA2-
LBD Agonists
The percentages of peptides, for (A) 123B9, (B)
YNH, (C) 123B7, (D) YSA, (E) 123B4, (F) YSA-9mer,
remaining at each time point relative to time 0 are
calculated from peak area ratios in relation to the
internal standard after incubation with fresh rat
plasma at 37C. Peptides are run in duplicate
(green and line lines) with a positive control known
to be degraded in plasma.suggest that like YNH-L2-PTX (or YSA-L2-PTX), 123B9-L2-PTX
is also an EphA2 agonist.
These studies show that 123B9 is a selective agonist for
EphA2, hence providing the impetus to further evaluate the abil-
ity of 123B9 conjugates to perform targeted drug delivery inmice
models of cancer.
In Vivo Toxicity and Efficacy Studies in Mice Models of
Pancreatic Cancer and Metastatic Melanoma
We have previously reported the enhanced anti-cancer proper-
ties of YSA-PTX, YNH-PTX, and dYNH-PTX drug conjugates
relative to PTX alone in PC3 xenograft models (Barile et al.,
2014;Wang et al., 2012, 2013). To further investigate the efficacy
of our agents in delivering PTX to cancer cells, we used two addi-
tional mouse models: a pancreatic cancer xenograft model and
a metastatic melanoma model. We compared our conjugates
with free PTX in the xenograft model and with albumin-bound
PTX (Abraxane) in the melanoma model. As mentioned above,
123B9-L2-PTX was synthesized using a similar synthetic
approach to that used for the syntheses of 123B9 and YNH-
L2-PTX (Barile et al., 2014). Preliminary toxicity studies estab-
lished the dose and regimen used in these efficacy studies,
similar to what we reported recently (Barile et al., 2014).
123B9-L2-PTX toxicity was assessed by injecting 150 mg/kg
(n = 4), 75 mg/kg (n = 3), or 50 mg/kg (n = 3) into the tail vein of
homozygous athymic nude mice three times per week for
2 weeks. The average body weight was recorded for 40 daysChemistry & Biology 22, 876–887, July 23, 2015after the first administration to monitor
latent toxicity. Mice that received the
highest dose (150 mg/kg, which is equiv-
alent to 20 times the reported PTX
maximum tolerated dose [MTD] in hu-
mans) were sacrificed after two injections
because of the loss of >10% of their body
weight. In contrast, the mice receiving
75 mg/kg and 50 mg/kg tolerated the
treatment without showing any adverse
signs of toxicity.
The effects of 123B9-L2-PTX or PTX on
tumor growth were tested using a pancre-
atic cancer xenograft model: pancreatic
cancer MIA PaCa-2-luciferase cells (5 3
106) were used to establish bilateral sub-
cutaneous tumors on the flanks of 8- to
10-week-old male athymic nude mice.
Mice received vehicle control, PTX, orour conjugated agent eight times during the course of a
4-week treatment protocol (two times per week). Tumor growth
in the untreated control group was typical for these cell lines (Van
Laar et al., 2004; Yan et al., 2009; Yip-Schneider et al., 2007). In
this experiment, we chose a sub-efficacious dose of PTX in the
hope that the targeted delivery agent would accumulate a
greater amount of drug at the tumor site, hence increasing the
efficacy. Similar to what we have recently observedwith prostate
cancer xenografts and YNH-L2-PTX (Barile et al., 2014), mice in
the 123B9-L2-PTX treatment group (7.5 mg/kg) showed signifi-
cant inhibition of tumor growth (p < 0.0001) compared with
mice treated with an equimolar dose of PTX (2.5 mg/kg) or un-
treated (Figure 4A). These findings suggest that accumulation
of the drug at the tumor site was effective with these pancreatic
cancer cells. During the 4weeks of the efficacy study, no signs of
adverse toxicity were observed in any of the treated mice.
EphA2 expression is associated with increased metastatic
behavior of cancer cells. In addition, EphA2 expression is
increased in the endothelium of the tumor vasculature, indepen-
dent of the expression levels of the receptor in the tumor. To
establish whether 123B9-L2-PTX is also effective in targeting
metastases in vivo, we used a melanoma lung colonization and
metastases model in which B16-F10-luc-G5 mouse melanoma
cells (5 3 105) were injected through the tail vein of male nude
mice, resulting in colonization of the lungs and other organs.
Lung signals were visible on day 0 when injecting with 5 3 105
cells. Mice were grouped based on equal lung signals atª2015 Elsevier Ltd All rights reserved 881
Figure 3. Comparative Biophysical and Cellular Activity of 123B9
(A) Chemical structure of 123B9-L2-PTX.
(B) The Kd values of 123B9-L2-PTX, EphA2-LBD, as determined by ITC measurements, resulting in 2.0 mM. The selectivity of 123B9-L2-PTX for the EphA2
receptor is demonstrated by testing the agent against EphA3-LBD and EphA4-LBD by ITC. No significant binding is detected to these closely related LBDs.
(C) Prostate cancer PC3M cells were treated for 1 hr with 0.2 mg/ml ephrin-A1 Fc or 100 mM YNH-L2-PTX, 123B9-L2-PTX, or its scrambled control XDP-L2-PTX
(see Supplemental Information). EphA2 immunoprecipitates were probed with an anti-phosphotyrosine antibody (pTyr) and reprobed with an anti-EphA2
antibody.day 0 and subsequently treated with either 60 mg/kg 123B9-L2-
PTX (IV dissolved in 85% PBS, 5% DMSO, and 10% Tween-80;
this amount is equivalent to 20 mg/kg of PTX) or a nanoparticle
albumin-bound PTX (Abraxane, Celgene) in amounts equivalent
to 20 mg/kg PTX. Mice were imaged dorsally and analyzed using
an IVIS imaging box. Macromolecules and ADCs may have
intrinsically poorer tissue penetration than small molecules.
They may show reduced activity against metastases compared
with unconjugated drugs (Deutscher, 2010; Li and Cho, 2010).
In this second in vivo experiment, we wanted to assess whether
our targeted delivery agent was more effective compared with
Abraxane at targeting metastases. Therefore, an effective dose
of Abraxane and an equivalent dose of 123B9-L2-PTX, both
delivering 20 mg/kg of PTX, were used. Signals in the lungs
and other metastatic signals appeared after 1 week and the
experiment was terminated at day 14 (Figures 4B and 4C).
Mice from each group that exhibited stronger signals in the tail
vein at day 14 (with intensity greater than 4.7 3 106 p/s) were
not further considered in the analyses, as it appeared that the
initial injections of tumor cells was unsuccessful. At day 14, as882 Chemistry & Biology 22, 876–887, July 23, 2015 ª2015 Elsevier Lexpected with this model, extensive signals in the lungs and
other sites were visible. In both the Abraxane- and 123B9-L2-
PTX-treated groups, metastasis appeared to be significantly in-
hibited compared with the control group (p < 0.001, Figure 4B,
upper panel). Similarly, both agents were equally effective in in-
hibiting lung colonization (Figure 4B, lower panel). However,
Abraxane was not effective in preventing metastases to other
organs, as signal there was similar to the untreated control. In
contrast, 123B9-L2-PTX was remarkably effective in inhibiting
metastatic colonization in other sites (Figure 4B lower panel
and Figure 4C; p < 0.001).
DISCUSSION
Currently, ADCs represent most tumor-homing agents under
clinical investigation. ADCs recognize tumor sites via specific
antibody/antigen interactions. However, because of the large
size of these molecules and non-specific uptake by mononu-
clear phagocytes, antibodies often have difficulty penetrating
tumor tissues (Deutscher, 2010; Li and Cho, 2010). In addition,td All rights reserved
Figure 4. In Vivo Efficacy Studies with 123B9-L2-PTX
(A) 123B9-L2-PTX inhibits human MIA PaCa-2 pancreatic cancer tumor growth in vivo to a greater extent than PTX in a xenograft study. Tumor volumes are
measured by caliper and reported as averaged ± SE. Asterisks show significance between the 123B9-L2-PTX group and both the PTX and control groups
(p < 0.0001 in both cases) (n = 5 mice/group). No signs of adverse toxicity, as determined by body weight, were observed in any of the groups during the
treatment.
(B and C) 123B9-L2-PTX inhibits melanoma cell proliferation and metastasis. B16-F10-luc-G5 cells (5 3 105) are injected IV through the tail vein of male nu/nu
mice to allow colonization of the lungs and other organs. Mice were imaged from dorsal views at day 0 and mice having similar signal intensities in the lungs were
selected and grouped for treatments (n = 6 receiving three times a week for 2 weeks 60 mg/kg 123B9-L2-PTX dissolved in 85% PBS, 5% DMSO, and 10%
Tween-80, I.V.; this amount is equivalent to 20mg/kg of PTX; and Abraxane in amounts equivalent to 20mg/kg PTX, IV three times aweek for 2 weeks) and control
(n = 8; receiving only vehicle). Mice imaged at day 14 via luciferin delivered by intraperitoneal injection are reported (C) and areas of fluorescence are quantified
and plotted (B). For the statistical comparisons we used two-way ANOVA analyses (GraphPad). *p < 0.05, ***p < 0.001, ns = not significant.the use of antibodies as tumor-homing agents presents other
challenges, such as the preparation and formulation of homoge-
neous ADCs and the relatively high cost and complexity of
manufacturing. Compared with antibodies, peptides exhibit
many desirable characteristics, including improved tissue pene-
tration, low immunogenicity, acceptable stability and integrity
in vivo, and, above all, ease of synthesis and conjugation with
several agents (Deutscher, 2010; Lee et al., 2010; Li and Cho,
2010).
As EphA2 is highly expressed in cancer cells and not normal
cells, it is an attractive target for the development of cancer-spe-Chemistry & Biology 22,cific delivery agents. In our previous studies, a first-generation
EphA2-specific peptide, YSA, was conjugated to PTX (Barile
et al., 2014; Wang et al., 2012, 2013). The conjugate resulted in
a significant increase in drug delivered to tumors compared
with administration of free PTX. However, the short t1/2 of YSA
limited its tumor-homing potential. To improve the stability of
the EphA2-specific peptide, a second generation of peptides,
YNH and dYNH, were developed by incorporating unnatural res-
idues in the YSA sequence (Barile et al., 2014; Wang et al., 2012,
2013). These modifications significantly increased the peptide
stability, especially for dYNH, which had a 10-fold improvement876–887, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 883
relative to YSA. However, this improved stability came at the
expense of binding affinity for the EphA2-LBD. The presence
of a d-tyrosine on the N terminus caused a significant loss
(over 10-fold) in the binding affinity (Barile et al., 2014; Wang
et al., 2013), suggesting the importance of the N-terminal residue
on both peptide stability and the binding affinity. Based on these
observations, we sought to optimize the N-terminal residues of
our peptides with the hope of balancing stability in vivowith bind-
ing affinity for the EphA2-LBD.
Here, we replaced the N-terminal d- or l-tyrosine of the dYNH
or YNH peptides, respectively, with tyrosine mimetics lacking
the amino group. Through 1D 1H NMR-based binding affinity
evaluations (Figure 1; Table 1) and direct binding assays (ITC),
(Table 2) we found that 123B9 binds to EphA2 with an affinity
that is similar to that of YNH and hence higher than dYNH. More-
over, and most noteworthy, stability assays indicated that 90%
of 123B9 remained intact after a 120-min incubation with rat
plasma, representing a significant improvement compared with
YNH, which had a t1/2 < 15 min in the same assay (Figure 2).
When administered IV in mice, 123B9 was remarkably stable,
with a t1/2 greater than 4 hr compared with a relatively short
t1/2 of YNH (<15 min). These results clearly indicate that our
P-1 optimization strategy successfully identified a novel EphA2
ligand with superior stability in plasma and in vivo.
The high similarity of the [15N, 1H]-HSQC spectra of the
EphA2-LBD acquired in the presence of 123B9 or YNH sug-
gested that the P-1 modification had no significant effect on
the overall binding pose of the peptide (Figures 1B–1D). Accord-
ingly, 123B9-L2-PTXwas synthesized (Figure 3) and tested in tis-
sue culture and in vivo assays. 123B9-L2-PTX was effective in
activating the EphA2 receptor in a human prostate cancer cell
line, similar to our previously reported YNH-L2-PTX drug conju-
gate (Figure 3). In contrast, the scrambled peptide drug conju-
gate (XDP-L2-PTX) did not show such activity. We further
assessed the toxicity of 123B9-L2-PTX by injecting high doses
of the agent IV to homozygous athymic nude mice three times
per week for 2 weeks. Toxicity was assessed by measurements
of average body weight. We found that mice that received the
highest dose (150 mg/kg, which is equivalent to approximately
50 mg/kg of PTX) had to be sacrificed after two injections
because of the loss of over 10%of body weight. On the contrary,
mice receiving 75mg/kg or 50mg/kg, corresponding to doses of
PTX of approximately 25 mg/kg or 16.7 mg/kg, respectively,
tolerated the treatment well without showing any adverse signs
of toxicity. These doses correspond to approximately ten times
and 6.7 times the MTD of PTX in humans; the single dose MTD
for PTX in mice is < 30 mg/kg (Singla et al., 2002; Zhang et al.,
2013). Taken together, these data indicate that 123B9-L2-PTX
was less toxic than unconjugated PTX. Moreover, the cell-based
data (Figure 3C) with 123B9-L2-PTX compared with its scram-
bled conjugate, XDP-L2-PTX, clearly indicated that 123B9 was
selective in activating EphA2 in prostate cancer cells. We previ-
ously also demonstrated that scrambled YSA and/or YNH pep-
tides conjugated to PTX did not activate the EphA2 receptor in
cells. In addition, these scrambled-PTX conjugates were not
effective at inhibiting tumor growth in vivo (Barile et al., 2014;
Wang et al., 2012, 2013).
Our current and previous studiesmotivated us to further inves-
tigate the efficacy of 123B9-L2-PTX in additional animal models:884 Chemistry & Biology 22, 876–887, July 23, 2015 ª2015 Elsevier La pancreatic cancer xenograft model and amelanoma lung colo-
nization and metastases model (Figure 4). The ability to inhibit
tumor growth in pancreatic MIA PaCa-2 cells by our agent was
in agreement with our previous studies with prostate cancer cells
PC3, in which we found increased levels of PTX in tumors from
mice that were administered with YSA-PTX compared with
mice that were treated with a similar dose of unconjugated
PTX (Wang et al., 2012). Of note is that both PC3 and MIA
PaCa-2 cells express increased levels of EphA2. These studies
suggested that it might also be beneficial to conjugate our pep-
tides to other drugs such as gemcitabine, currently used as the
first-line treatment for pancreatic cancer.
The studies with the mouse model of melanoma are perhaps
evenmore intriguing. In this model, B16-F10-luc-G5 mouse mel-
anoma cells (53 105) injected via the tail vein colonized the lungs
and other organs. Mouse and human EphA2 share 94.1%
sequence identity in their LBDs and 100% sequence identity
when considering just the ephrin binding site, so our agent tar-
gets both the human and mouse receptor. Although the B16-
F10 cell line does not express high levels of EphA2 (Parri et al.,
2009), EphA2 appears to be induced in tumor-associated
vascular endothelial cells, as suggested by the positive effects
of an EphA2-derived vaccine in a B16-F10 model (Hatano
et al., 2004). Hence, similar to what we have recently observed
with low EphA2 expressing renal carcinoma cells (Wang et al.,
2013), our hypothesis is that our agents may target the tumors
or their associated vasculature or both.
When tested in the B16-F10 model, both Abraxane and
123B9-L2-PTX were equally effective in inhibiting lung coloni-
zation and overall metastases (Figure 4B) compared with con-
trol groups (p < 0.001 and p < 0.05, respectively). In contrast,
Abraxane was much less effective in targeting other metasta-
ses compared with 123B9-L2-PTX (Figures 4B and 4C) (Abrax-
ane versus control not significant; 123B9-L2-PTX versus
control p < 0.001). It is tempting to speculate that this effect
may be attributable to two possible causes: the peptide may
possess improved tumor penetrating abilities compared with
Abraxane; 123B9 may deliver PTX to metastatic cells or
tumor-associated vascular endothelial cells expressing EphA2
or both more effectively than Abraxane. While these hypothe-
ses remain to be experimentally verified, our current data
suggest that 123B9 represents a unique and unprecedented
pharmacological tool to further investigate the role of EphA2
in tumor progression and metastasis in vitro and in vivo. Obvi-
ously, no targeted delivery agent, whether a peptide mimetic or
an ADC, can claim to act only on tissues expressing the tar-
geted receptor. Eventually, drugs can get cleaved from the
agent and/or the conjugates can get degraded, eliminated,
and metabolized in many complex ways. Ultimately, the prom-
ise of such targeted agents is to increase the therapeutic
window of the chemotherapeutic agent compared with the un-
conjugated drug. This is what our data collectively seem to
indicate. In conclusion, our studies suggest that conjugating
123B9 with therapeutics or diagnostics, perhaps via functional-
ized nanoparticles or via direct use as single peptide conju-
gates as reported here, could represent a promising strategy
for the development of novel targeted therapies for cancer.
Finally, our strategy for optimizing peptide into a more stable
mimetic is of general applicability and could prove useful intd All rights reserved
the derivation and optimization of other potentially interesting
tumor-homing peptide mimetics.
SIGNIFICANCE
In oncology research, the development of novel targeted
drug delivery strategies requires the design of potent and
selective agents that are amenable to conjugation with che-
motherapeutics. Although peptides represent potentially
excellent tumor-homing agents for this purpose, they often
get degraded too rapidly in vivo. Here, by using a combina-
tion of NMR-guided structure-activity relationships and
biochemical and cellular studies, we derived a novel peptide
mimetic that targets the ligand-binding domain of the recep-
tor tyrosine kinase EphA2 with great selectivity. The peptide
mimetic was very stable in plasma and in vivo. Conjugates
with the chemotherapeutic drug paclitaxel were effective
in a variety of studies, both in tissue culture and animal
models of cancer proliferation and metastasis. In particular,
conjugating 123B9 to paclitaxel resulted in an agent that was
significantly more effective than the unconjugated drug in
both a pancreatic cancer xenograft model and a melanoma
lung colonization and metastases model. These findings
suggest that the agent may be effective not only in inhibiting
tumor growth but also in targeting the tumor vasculature
and/or circulating metastatic cancer cells. Therefore, our
data suggest that conjugating 123B9 with possibly other
therapeutics or diagnostics, perhaps via functionalized
nanoparticles or via direct use as single peptide conjugates
such as reported here, could represent a promising strategy
for the development of novel targeted therapies for cancer.
The new agent may also be useful for future biodistribution
studies in mice, perhaps using ephA2–/– mice to further
investigate the role of this receptor in vivo. Finally, our pep-
tide optimization strategy is generally applicable and could
be useful in the derivation and optimization of other poten-
tially interesting pharmacologically active peptidemimetics.
EXPERIMENTAL PROCEDURES
General
Unless otherwise indicated, all anhydrous solvents were commercially ob-
tained and stored in Sure/Seal bottles under nitrogen. All other reagents and
solvents were purchased as the highest grade available and used without
further purification. Thin-layer chromatography (TLC) analysis of reaction mix-
tures was performed using Merck silica gel 60 F254 TLC plates, and visualized
using UV light. NMR spectra were recorded on Jeol 400-MHz instruments or
Bruker 600-MHz instruments. Chemical shifts (d) are reported in parts per
million (ppm) referenced to 1H (Me4Si at 0.00). Coupling constants (J) are
reported in Hz throughout. Mass spectral data were acquired on a Bruker
Daltonic Autoflex MALDI-TOF instrument. Purity of all compounds was deter-
mined by HPLC Breeze from Waters using an Atlantis T3 5 mm 4.6 3 150 mm
reverse phase column and compounds detected at l = 254 nm or 220 nm.
Peptide Synthesis
All linear peptides were assembled using standard Fmoc peptide synthesis
protocol with the Rink amide resin on 433A Peptide Synthesizer (Applied Bio-
systems). For each coupling reaction, 10 equiv of Fmoc-amino acid, 0.45 M
solution of HOBt/HBTU (9 equiv) in DMF, 2 M solution of DIEA in NMP were
used. The coupling reaction was allowed to proceed for 9 min. Fmoc depro-
tection was performed by treating the resin-bound peptide with 20% piperi-
dine in DMF for 10 min. The peptide was cleaved from the resin by treatingChemistry & Biology 22,the resin with a cleavage cocktail containing 94% TFA, 2% water, 2% triiso-
propylsilane, 2% phenol for 3 hr. All protecting groups were also removed
during this cleavage reaction. TFA was removed under reduced pressure
and the peptides were precipitated in diethyl ether, centrifuged, and washed
with diethyl ether before drying in high vacuum. The crude peptides were
purified by preparative reverse phase high-performance liquid chromatog-
raphy (HPLC). The final compound was characterized by NMR and MALDI-
MS. All compounds were > 95% purity. The synthetic approaches for
123B9-L2-PTX and the scrambled XDP-L2-PTX are similar to what we have
recently reported (Barile et al., 2014), and hence are reiterated in the Supple-
mental Information.
Protein-Ligand Interaction Studies
The purified EphA protein (EphA4-LBD, EphA3-BD, and EphA2-LBD) were dis-
solved to a final concentration of either 10 mM or 100 mM in 50 mM phosphate
buffer (pH 6.5), containing 100 mM NaCl. NMR spectra were acquired on 600-
and 700-MHz Bruker Avance spectrometers equipped with TCI cryoprobes.
All NMR data were processed and analyzed using TOPSPIN2.1 (Bruker Bio-
spin) and SPARKY3.1 (University of California, San Francisco). Compound
binding was detected at 27C by comparing either the 2D-[15N, 1H]-HSQC
spectra of 100 mM EphA2 LBD in absence and presence of compounds at
200 mM or the 1D-1H spectra of 10 mM EphA2 LBD in absence and presence
of compounds at 100. ITC were measured with Model ITC200 from
Microcal/GE Life Sciences.
Plasma Stability
Test compound solutions were incubated (1 mM, 2.5% final DMSO concentra-
tion) with fresh rat plasma at 37C. The reactions were terminated at 0, 30, and
60 min by the addition of two volumes of methanol containing internal stan-
dard. After protein precipitation and centrifugation, the samples were analyzed
by LC-MS. The percentage of parent compound remaining at each time point
relative to the 0-min sample is calculated frompeak area ratios in relation to the
internal standard. Compounds were run in duplicate with a positive control,
diltiazem (not shown).
MTD Studies
123B9-L2-PTX toxicity was assessed by injecting 150 mg/kg (n = 4), 75 mg/kg
(n = 3), and 50 mg/kg (n = 3) into the tail vein of 4- to 5-week-old female homo-
zygous athymic nudemice of 22 g as average weight (strain code: 490, Charles
River) three times per week for 2 weeks. The compound was dissolved in a
mixture of 85% PBS, 10% Tween-80, and 5% DMSO and injected in a
200-ml final volume. The animals were weighed daily starting on the first day
of treatment and after the cessation of compound injections (40 days total)
to monitor body weight as sign of toxicity.
Immunoprecipitation and Immunoblotting
PC-3M-luc-C6 cells were grown in RPMI containing 10% fetal bovine serum
and sodium pyruvate. Cells were serum-starved for 1 hr in serum-free
medium and treated for 1 hr with 0.2 mg/ml ephrin-A1 Fc (as a positive control),
0.2 mg/ml human Fc (as a negative control), 100 mM YNH-L2-PTX, 123B9-L2-
PTX, or XDP-L2-PTX. The cells were lysed in modified RIPA lysis buffer
(150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate,
0.1% SDS, 20 mM Tris [pH 8.0]) containing protease inhibitors and 1 mM
sodium orthovanadate. For immunoprecipitations, the lysates were incubated
with 1 mg anti-EphA2 antibody (Millipore-Upstate) immobilized onGammaBind
Sepharose beads (GE Healthcare Life Sciences). Immunoprecipitates were
probed by immunoblotting with an anti-phosphotyrosine antibody (Millipore),
or an anti-EphA2 antibody (Life Technologies/Invitrogen).
Pancreatic Cancer Xenograft Model
5 3 106 MIA PaCa-2-luciferase cells were used to establish bilateral subcu-
taneous tumors on the flanks of 8- to 10-week-old male athymic nude mice.
Treatment began when tumors reached 100 mm3. All drugs were diluted in
10% Tween-80, 10% DMSO, and 80% PBS and administered by tail vein
injection twice per week for 4 weeks, a total of eight injections. PTX was given
at a dose of 2.5 mg/kg. 123B9-L2-PTX was given at an equimolar dose to PTX.
Tumors were measured twice per week using calipers and tumor volumes
were calculated using the formula volume = 0.5*(l*w2).876–887, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 885
Melanoma Lung Colonization and Metastases Model
B16-F10-luc G5 mouse melanoma cells were purchased from Xenogen
Bioscience and grown as described by the supplier in RPMI 1640 supple-
mented with GlutaMax (Life Technologies). 500,000 trypsin dissociated cells
were suspended in 0.1 ml of Dulbecco’s PBS and injected IV through the
tail vein of 8-week female athymic nude-Foxn1nu purchased from Harlan
Laboratories. The time line of this experiment involved luciferase activity
being imaged dorsally 10 min after luciferin injection with a 3-min dorsal
exposure using the Xenogen IVIS imaging system. Animals received intraper-
itoneal injection of luciferin (150 mg/kg) and were anesthetized with 3%
isoflurane gas. Mice with unsuccessful IV injections were excluded from
further use. One control group (n = 8) received only vehicle. Two groups
(n = 6) each received either Abraxane or 123B9-PTX (in 85% PBS, 5%
DMSO, 10% Tween-80) at 20 mg/kg (PTX equivalents) three times weekly
by IV injection. Animals were imaged twice weekly after injection. The photon
signals of the lung area were compared with the sum of all other areas. Met-
astatic signals begin to appear after 1 week and the experiment was termi-
nated at day 14.
SUPPLEMENTAL INFORMATION
Supplemental Information includes synthetic procedures and analytical data
and can be found with this article online at http://dx.doi.org/10.1016/j.
chembiol.2015.06.011.
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